Press Release: Bioserve India Launches Advanced Stem Cell Products
22 July 2024
Hyderabad, India – July 2024 – Bioserve India is excited to announce the launch of its advanced stem cell products in India. These new products from REPROCELL aims to support innovation in scientific research and drug development, supportin...
REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells
30 May 2024
REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for generation of Human Induced Pluripotent Cells (hiPSC) and Human Mesenchymal Stem Cells (hMSC) for human therapeutic applications. BELTSVILLE, ...
PRESS RELEASE: Bioserve Biotechnologies and RISVI Trading Announce New Distributorship Agreement in Qatar
17 May 2024
Hyderabad, India and Doha, Qatar – May 6, 2024 – Bioserve Biotechnologies (India) Private Limited, a leader in molecular biology products, is excited to announce a new distributorship agreement with RISVI Trading W.L.L., a renowned trading ...
PRESS RELEASE: Our StemRNA Clinical Seed iPSCs Power Breakthrough in Women's Health!
16 May 2024
REPROCELL is thrilled to share groundbreaking research facilitated by our StemRNA™ Clinical Seed iPSCs, a pivotal step forward in redefining women's healthcare. In tandem with our partner Gameto, a female-led biotechnology company, we provi...
PRESS RELEASE: REPROCELL Announces Partnership with Nova Natura UAB, Expanding Distribution Reach in Baltic Region
14 May 2024
Glasgow, UK & Kaunas, Lithuania – REPROCELL, a leading player in the field of drug discovery, is thrilled to announce its strategic partnership with Nova Natura UAB, a prominent distributor specializing in laboratory instruments, reagents, ...
New from REPROCELL: GMP Grade Stem Cell Master Cell Bank Service Expansion
18 April 2024
REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for the generation of Human Induced Pluripotent Cells (hiPSC) in Beltsville for human therapeutic applications. REPROCELL has been producing clini...
[PRESS RELEASE:] REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)
08 February 2024
REPROCELL currently has two clinical pipelines under research and development: (1.) the stem cell product Stemchymal for spinocerebellar ataxia; (2.) iPSC-derived neuroglial cells for ALS (Amyotrophic Lateral Sclerosis). REPROCELL will soon...
Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu
31 January 2024
REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant, that is located in Larrabetzu, Spain. Histocell's manufacturing plant produces cell ther...
Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives
15 January 2024
SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cel...
End of 2023 Newsletter
15 December 2023
The end of the year might be approaching, but we’re not winding down at REPROCELL. The final half of 2023 has brought new services, collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This inclu...